J&J Consulting Group- FDA Regulatory Compliance
- 1101 California Ave Suite 100 Corona CA 92881
- Info@jjccgroup.org
- (800) 999-7781
FDA PMTA Regulatory Consulting for Tobacco and ENDS Products
Expert FDA PMTA consulting for tobacco, vape, and ENDS products — covering scientific evidence, toxicology, behavioral studies, manufacturing data, and full submission management to ensure FDA authorization and market access.
Call for Appoinment
+ 1 (800) 999-7781
Understanding Premarket Tobacco Product Applications (PMTA)
What is a Premarket Tobacco Product Application (PMTA)?
A Premarket Tobacco Product Application (PMTA) is the FDA pathway that every new tobacco or nicotine product must follow before it can be legally marketed in the United States. Authorized under Section 910(b) of the Federal Food, Drug, and Cosmetic (FD&C) Act and implemented through 21 CFR Part 1114, the PMTA process requires manufacturers to demonstrate — through robust scientific evidence — that permitting the marketing of their product is “appropriate for the protection of public health (APPH).”
This standard means the FDA must weigh both the risks and benefits of your product to users and non-users, including potential cessation benefits for current tobacco users and the risk of initiation among non-users, especially youth. Since the first PMTA authorization was granted in 2015, the FDA's review standards have grown significantly more rigorous — making expert regulatory guidance essential to submission success.
At JJCC Group, we guide tobacco manufacturers, brand owners, importers, and retailers through every stage of the PMTA journey — from pre-submission planning to FDA marketing authorization and post-market compliance.aragraph here
Overview of PMTAs
Who Must Comply? Brand Owners, Manufacturers, and Retailers
PMTA compliance isn’t limited to manufacturers. Under 21 CFR Parts 1100, 1107, 1114, 1140, and 1143, the following stakeholders have specific obligations:
Manufacturers: Must submit a PMTA for each new tobacco product, comply with FDA’s manufacturing and good practices requirements, maintain detailed records, and submit periodic reports post-authorization.
Brand Owners / Importers / Responsible Persons: Must ensure that every product sold under their name has an active PMTA marketing granted order. They are also responsible for labeling, advertising compliance, and adverse event reporting.
Retailers and Distributors: Cannot legally sell or distribute any tobacco product without FDA marketing authorization. Selling unauthorized products can result in warning letters, civil money penalties, product seizures, and import refusals — and the FDA actively coordinates with U.S. Customs and Border Protection to seize illegal products at the border.
JJCC Group helps each stakeholder understand their role, responsibilities, and compliance obligations under the applicable CFR sections.
Population Risks
FDA evaluates overall risks and benefits to users and nonusers before authorizing new products.
Population Risks
FDA evaluates overall risks and benefits to users and nonusers before authorizing new products.
Current Users
FDA considers if current tobacco users are likely to stop using products with availability.
Current Users
FDA considers if current tobacco users are likely to stop using products with availability.
Non-Users
FDA assesses whether non-users may start using tobacco if the new product launches.
Non-Users
FDA assesses whether non-users may start using tobacco if the new product launches.
What Product Require a PMTA
Under the FDA's "deeming rule," any product that meets the definition of a tobacco product under the FD&C Act must obtain FDA marketing authorization. The following products require a PMTA submission:
Electronic Nicotine Delivery Systems (ENDS): e-cigarettes, vape pens, vape pods, e-liquids, disposable vapes, and refill solutions
Nicotine Pouches: tobacco-free oral nicotine pouches and lozenges
Cigars and Cigarillos: premium, large, and small cigars
Hookah and Waterpipe Tobacco: including shisha and accessories
Pipe Tobacco
Smokeless Tobacco: snus, chewing tobacco, dissolvables
Heated Tobacco Products (HTPs)
Roll-Your-Own (RYO) Tobacco
Any new or modified tobacco product introduced or changed after February 15, 2007
This includes any change in design, components, ingredients, nicotine content, flavor, or delivery system — even minor modifications can require a new or supplemental PMTA.
- 30+ years combined regulatory expertise
- Successfully submitted hundreds PMTA applications
- FDA approvals for new tobacco products
- Comprehensive consumer perception studies completed
- Expertise in HPHC reporting compliance
Our Achievements
Key milestones andachievements
Process
PMTA Review Process
The PMTA review process includes pre-submission meetings, acceptance review, filing review, substantive scientific evaluation, and post-market reporting compliance.
A voluntary formal meeting between the applicant and FDA to discuss a planned PMTA submission for a tobacco product.
- Meeting granted letter or
- Meeting denial letter
- Meeting minutes letter (if the meeting is granted and held)
- Acceptance letter or
- Refuse to accept (RTA) letter
- Filing letter or
- Refuse to file (RTF) letter
- Deficiency letter: Additional information is needed to complete a scientific review. The letter will specify the number of days an applicant has to respond.
- Environmental information request letter: FDA made a scientific decision to issue a marketing granted order; however, the applicant is required to provide information for environmental considerations before a marketing granted order can be issued.
Clinical study requires meticulous planning and careful execution. Failure to adhere to well-thought study protocol/regiment, may lead to a waste of resources
- Marketing granted order letter or
- Marketing denial order letter
Submit PMTA
How to Submit a PMTA
Request IAM Account
Apply for an IAM account if your company does not already have one, enabling secure access to FDA systems.
Prepare Electronically
Complete your PMTA application using the eSubmitter software and the CTP Transmittal Form template for accurate submission.
Submit Online
Once prepared, submit your PMTA online via the CTP Portal for FDA review and consideration.
Get Expert Help
Ready to Navigate the PMTA Process Confidently?
How to Prepare
The FDA PMTA Review Process: What You Need to Know
Once submitted, your PMTA undergoes a structured, multi-phase review by the FDA’s Center for Tobacco Products (CTP). Understanding each phase helps you plan, prepare, and respond effectively.
Phase 1: Acceptance Review
An initial administrative review confirming that the product falls under CTP jurisdiction and that the submission meets the statutory and regulatory requirements outlined in 21 CFR § 1114.27(a)(1). Outcome: Acceptance letter or Refuse to Accept (RTA) letter.
A threshold determination assessing whether the application contains sufficient information to permit a full scientific evaluation. Outcome: Filing letter or Refuse to File (RTF) letter under § 1114.27(b)(1).
Phase 3: Substantive Scientific Review
The core of the PMTA evaluation. FDA scientists conduct a deep review of your toxicology, chemistry, behavioral, and manufacturing data — assessing whether your product is "appropriate for the protection of public health." The FDA may issue Deficiency Letters requesting additional information, and applications may be referred to the Tobacco Product Scientific Advisory Committee (TPSAC). Outcome: Continued review, deficiency response, or final action.
Phase 4: Final Decision & Post-Market Compliance
The FDA issues either a Marketing Granted Order (MGO) authorizing market entry, or a Marketing Denial Order (MDO) prohibiting sales. Authorized products are subject to ongoing post-market reporting, adverse experience reporting, and supplemental PMTAs for any product changes.
What to Expect: Timeline & Investment
The PMTA process is a multi-year regulatory commitment. Most manufacturers should plan for:
1–2 years to gather scientific data and prepare submission documents
6–12+ months for FDA acceptance, filing, and substantive review
Ongoing post-market reporting and supplemental filings after authorization
Without proper preparation, applications frequently receive RTA, RTF, or deficiency letters — costing valuable time and resources. JJCC Group helps you avoid these pitfalls with proven submission strategies and FDA-aligned documentation.
Why Choose JJCC Group for PMTA Submission Services
Proven regulatory expertise across ENDS, nicotine pouches, cigars, and emerging tobacco categories
End-to-end submission management — from strategy to authorization
Scientific and technical depth in toxicology, chemistry, and manufacturing
FDA-aligned documentation that minimizes deficiencies and review delays
Ongoing post-market compliance support to keep your products authorized and protected
Whether you're an established tobacco manufacturer, an emerging vape brand, or an importer entering the U.S. market, JJCC Group delivers the regulatory clarity, scientific rigor, and FDA expertise needed to bring your product to market and keep it there.
Best Compliance with 5 Star
99% Happy Clients
Testimonial
Trusted PMTA Regulatory Experts
Their PMTA expertise, documentation accuracy, and FDA communication support helped us avoid delays and regulatory setbacks.
Faqs
Frequently Asked Questions
What is a PMTA? and which products require one?
A Premarket Tobacco Product Application (PMTA) is the FDA pathway required for any new tobacco or nicotine product before it can be legally marketed in the United States. Under Section 910(b) of the FD&C Act and 21 CFR Part 1114, a PMTA is required for electronic nicotine delivery systems (ENDS/vapes), nicotine pouches, cigars, hookah/waterpipe tobacco, pipe tobacco, smokeless tobacco, heated tobacco products, and any new or modified tobacco product introduced after February 15, 2007.
Who is responsible for submitting a PMTA — the manufacturer, the brand, or the retailer?
he applicant — typically the manufacturer, brand owner, or importer — is responsible for submitting the PMTA and obtaining FDA marketing authorization. Retailers and distributors cannot legally sell tobacco products without an active Marketing Granted Order, but they are not the submitting party. JJCC Group helps each stakeholder understand their specific compliance obligations under 21 CFR Parts 1100, 1107, 1114, 1140, and 1143.
What does "Appropriate for the Protection of Public Health" (APPH) mean?
APPH is the legal standard the FDA uses to evaluate every PMTA. The agency weighs the risks and benefits of your product to both users and non-users — including potential cessation benefits for current tobacco users and the risk of initiation among non-users, especially youth. Demonstrating APPH requires robust scientific evidence across toxicology, chemistry, behavioral studies, and manufacturing controls.
What are the four phases of the FDA PMTA review process?
The FDA conducts a structured, four-phase review:
- Acceptance Review — confirms jurisdiction and basic regulatory requirements
- Filing Review — verifies the application contains sufficient information for scientific review
- Substantive Scientific Review — FDA scientists evaluate toxicology, chemistry, manufacturing, and behavioral data
- Final Action & Post-Market Compliance — results in a Marketing Granted Order (MGO) or Marketing Denial Order (MDO), followed by ongoing reporting obligations
How long does the PMTA process take?
The PMTA process is a multi-year commitment. Most manufacturers should plan for 1–2 years to gather scientific data and prepare the submission, followed by 6–12+ months for FDA review across acceptance, filing, and substantive evaluation. JJCC Group helps streamline timelines and avoid costly delays caused by incomplete submissions or deficiency letters.
